Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test Algorithms-Reference-Cited by-同舟云学术

Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test Algorithms

Published:2020-12-17 Issue:1 Volume:59 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Turbett Sarah E.¹²^ORCID,Anahtar Melis¹^ORCID,Dighe Anand S.¹,Garcia Beltran Wilfredo¹,Miller Tyler¹,Scott Hannah³,Durbin Sienna Marie³,Bharadwaj Maheetha³,Thomas Jason³,Gogakos Tasos S.¹,Astudillo Michael¹,Lennerz Jochen¹,Rosenberg Eric S.¹²,Branda John A.¹

Affiliation:

1. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

2. Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

3. Undergraduate Medical Education Program, Harvard Medical School, Boston, Massachusetts, USA

Abstract

Sensitive and specific severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic assays are needed to inform diagnostic, therapeutic, and public health decision-making. We evaluated three commercial serologic assays as stand-alone tests and as components of two-test algorithms. Two nucleocapsid antibody tests (Abbott IgG and Roche total antibody) and one spike protein antibody test (DiaSorin IgG) were included. We assessed sensitivity using 128 serum samples from symptomatic PCR-confirmed coronavirus disease 2019 (COVID-19)-infected patients and specificity using 1,204 samples submitted for routine serology prior to COVID-19’s emergence, plus 64 pandemic-era samples from SARS-CoV-2 PCR-negative patients with respiratory symptoms.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01892-20

Reference20 articles.

1. Interpreting Diagnostic Tests for SARS-CoV-2

2. Virological assessment of hospitalized patients with COVID-2019

3. Profile of RT-PCR for SARS-CoV-2: A Preliminary Study From 56 COVID-19 Patients

4. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

5. Gronvall G, Connell N, Kobokovich A, West R, Warmbrod KL, Shearer MP, Mullen L, Inglesby T. 2020. Developing a national strategy for serology (antibody testing) in the United States. Johns Hopkins Center for Health Security, Baltimore, MD. https://www.centerforhealthsecurity.org/our-work/publications/developing-a-national-strategy-for-serology-antibody-testing-in-the-US. Accessed 5 June 2020.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Seroprevalence of IgG Antibodies Against SARS-CoV-2 N Protein Among Vaccinated and Unvaccinated Subjects in Lahore, Pakistan;Acta Medica Bulgarica;2024-03-01

2. Vaccine-induced and hybrid immunity to SARS-CoV-2 after three or four doses of BNT162b2 - results from 22 months follow-up of a healthcare workers cohort, Israel, 2020-2022;International Journal of Infectious Diseases;2023-10

3. Validation of N Protein Antibodies to Diagnose Previous SARS-CoV-2 Infection in a Large Cohort of Healthcare Workers: Use of Roche Elecsys® Immunoassay in the S Protein Vaccination Era;Viruses;2023-04-07

4. Household Transmission of SARS-CoV-2 and Long-term Immunity in Children: A Prospective Study in Northern Spain;Pediatric Infectious Disease Journal;2022-11-29

5. Evaluation of two immunocromatographic tests for the detection of antibodies against SARS-CoV-2;Revista Española de Quimioterapia;2022-09-27